Research Article
You have full text access to this OnlineOpen article
Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: A multicenter active-surveillance report
Article first published online: 1 AUG 2003
DOI: 10.1002/art.11137
Copyright © 2003 by the American College of Rheumatology
Additional Information
How to Cite
Gómez-Reino, J. J., Carmona, L., Valverde, V. R., Mola, E. M. and Montero, M. D. (2003), Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: A multicenter active-surveillance report. Arthritis & Rheumatism, 48: 2122–2127. doi: 10.1002/art.11137
Publication History
- Issue published online: 1 AUG 2003
- Article first published online: 1 AUG 2003
- Manuscript Accepted: 22 APR 2003
- Manuscript Received: 17 JAN 2003
Funded by
- Agencia Española del Medicamento (Ministerio de Sanidad y Consumo)
- Spanish Society of Rheumatology
REFERENCES
- 1, , , , , , et al, the Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med 2000; 343: 1594–602.
- 2, , , , , , et al, the ATTRACT Study Group. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomized phase III trial. Lancet 1999; 354: 1932–9.
- 3. Anti-tumor necrosis factor therapies. Curr Opin Rheumatol 2001; 13: 164–9.
- 4, , , , , , et al. Tuberculosis associated with infliximab, a tumor necrosis factor α-neutralizing agent. N Engl J Med 2001; 345: 1098–104.
- 5SESPAS (Sociedad Española de Salud Publica). 2002 SEPAS report: investing in health. In: CabasesJM, VillalbiJR, AibarC, editors. Priorities for public health in Spain. Granada (Spain): Escuela Andaluza de Salud Publica; 2002. p. 21–42.
- 6, , , , , , et al, the EMECAR Study Group. Rheumatoid arthritis is associated to a four-fold increase in tuberculosis infection incidence in the pre-biologics era [abstract]. Arthritis Rheum 2001; 44 Suppl 9: S173.
- 7, , , . Experience with etanercept in an academic medical center: are infection rates increased? Arthritis Care Res 2002; 47: 17–21.Direct Link:
- 8, , , . Tuberculosis rates are not increased in rheumatoid arthritis (RA) [abstract]. Arthritis Rheum 2001; 44 Suppl 9: S105.
- 9, , . Pulmonary tuberculosis in patients with rheumatoid arthritis (four case reports). Rheumatol Int 2002: 21: 153–7.
- 10, . Late reactivation of spinal tuberculosis by low-dose methotrexate therapy in a patient with rheumatoid arthritis. Rheumatology (Oxford) 2001; 40: 341–2.
- 11, , , . Mycobacterium tuberculosis infection in patients with systemic rheumatic diseases: a case-series. Clin Exp Rheumatol 1999; 17: 289–96.
- 12, . Tuberculosis and rheumatoid arthritis (a propos of 4 cases). Ann Med Interne (Paris) 1996; 147: 375–7.
- 13, , , , , . Tuberculosis notification from 1987 to 1999 for the public health area of the community of Valencia (Spain). Arch Bronconeumol 2001; 37: 417–23.
- 14, . Management of tuberculosis in the United States. N Engl J Med 2001; 345: 189–200.
- 15, , , . Tuberculosis reports with etanercept (Enbrel) therapy [abstract]. Arthritis Rheum 2001; 44 Suppl 9: S78.

1529-0131/asset/olbannerleft.gif?v=1&s=897b81612b4ad6cae003112184adc709261d5f61)
1529-0131/asset/olbannerright.gif?v=1&s=04654f5ea3cbb01656383e0c0d04b16fd0a9a896)
1529-0131/asset/cover.gif?v=1&s=104d5c2bb8ef72deba26790b855af7ab80697a0e)